| Name | Title | Contact Details |
|---|
Vision Circuits is a Ottawa, ON-based company in the Computers & Electronics sector.
2020 Fusion is a Redwood City, CA-based company in the Computers and Electronics sector.
Camgian Microsystems was founded in December 2006, by CEO Dr. Gary Butler, with the vision of becoming a leader in combining innovative technologies in the areas of low-power microelectronics, sensors, wireless communications and data analysis to provide solutions that provide valuable decision analytics for customers in the government and commercial markets. To rapidly pursue this vision, in June 2007, Camgian merged with Theseus Logic, a Honeywell spin-out focused on low-power IC technologies and in February 2009 acquired the Cypress Semiconductor design center in Starkville, Mississippi. Camgian is a leader in developing advanced information technologies and solutions. From ultra-low power processors to advanced sensing platforms, Camgian engineers are pioneering leading-edge innovations that are enabling a new generation of high performance wireless information technologies and products for the defense, security, industrial and commercial markets. Camgian is headquartered in Starkville, Mississippi, with additional offices at the Stennis Space Center in Stennis, Mississippi.
Palomar Technologies, Inc. is a Carlsbad, CA-based company in the Computers & Electronics sector.
Xceleron believes that AMS technology and our expertise can get life-changing products (drugs and biobased) quickly and cost-effectively to people who need them. We work with integrity and an open mind and are driven by science and the spirit of collaboration. Founded in 1997 in York, UK, and now headquartered in Germantown, Maryland, Xceleron pioneered human microdose and microtracer techniques using AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I, and Phase II/III clinical trials. Xceleron’s experience is especially valuable because the characteristics of many contemporary small molecules (low solubility, long half-life and disproportionate human metabolites) mean that their early pharmacokinetic and metabolic characterization is critical to the cost-effectiveness of clinical development.